Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …

1Department of Hematology-Oncology" L. and A. Seràgnoli" University of Bologna, Bologna;
2Onco-Hematology Unit, University of Naples Federico II and CEINGE, Biotecnologie …

Diabetic nephropathy (DN) is the most common cause for end stage renal disease (ESRD).
Next to environmental factors, genetic predispositions determine the susceptibility for DN …

Objective: Molecular monitoring of chronic myeloid leukemia (CML) has been associated
with improved clinical outcomes during tyrosine kinase inhibitor therapy (TKI), yet recent …

Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic
myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the …

Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the
BCR/ABL1 oncogene. Although the disease can be kept under control using BCR/ABL1 …

During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic
myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the …

Chronic myeloid leukemia (CML) is a hematological disease accounting for about 15-20% of
all adult leukemias. The clinical and biologic advances achieved in such a malignancy …

Context.—Chronic myelogenous leukemia (CML) and the assessment of the BCR-ABL
transcript has become a new paradigm. Novel tyrosine kinase inhibitors as mainstream …

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal
chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well …